Neuroelectrical Biomarkers for Alzheimer's Disease Stages

NEw approacheS for The dIagnosis of AlzeiMer's diseAse Through neuroElectrical Changes in the Brain

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01880151

Acronym

ESTIMATE

Enrollment

Registered

2013-06-18

Start date

2013-07-12

Completion date

2019-01-31

Last updated

2021-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

Alzheimer's disease, Dementia, Prodromal, EEG, ERP, Biomarkers

Brief summary

Recent diagnostic criteria for Alzheimer's disease (AD) recognize an extended spectrum of AD stages as part of the disease, including a preclinical stage. This underscores the importance of early prognosis of AD when it is still possible to influence the course of the disorder. The investigators propose a comprehensive project which will target the data-driven modeling of the disease development. This goal will be achieved by creating and validating a battery of new sensitive biomarkers for clinical evaluation and prediction of AD in individuals. The AD-related brain changes will be assessed by noninvasive functional EEG measured during an episodic memory task in subjects at different stages of AD, as well as in healthy controls. The novel functional biomarkers will be extracted using a rigorous multistage selection procedure involving advanced methods for feature extraction, as well as statistics and classification for optimal selection. The ESTIMATE project will serve as a first step in an extensive array of research procedures which will enable the early clinical identification of Alzheimer's disease in elderly individuals who could then take advantage of preventive pharmaceutical therapies.

Interventions

DEVICEEEG

EEG recorded during a resting condition and during an episodic memory task condition

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

70 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Age: 70-85 years old * Presence of memory impairment * Completed educational level: middle school * Visual and auditory acuity: normal or corrected-to-normal

Exclusion criteria

* Monogenic AD * Presence of a neurological disorder * Stroke that has occurred in the last three months * Prohibited medications * Residence in skilled nursing facility * Illiteracy, is unable to count or to read * Claustrophobia

Design outcomes

Primary

Measure	Time frame
Frequency band charactersitics of the electrophysiological brain response	Baseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026